Citations (63)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Hiroyuki Sasabe, Toshihisa Koga, Masayuki Furukawa, Masayuki Matsunaga, Katsunori Sasahara, Kenta Hashizume, Yoshihiro Oozone, Immaculate Amunom, Mikako Torii, Ken Umehara, Eiji Kashiyama & Kenji Takeuchi. (2021) In vitro evaluations for pharmacokinetic drug-drug interactions of a novel serotonin-dopamine activity modulator, brexpiprazole. Xenobiotica 51:5, pages 522-535.
Read now
Read now
Sara Algeelani, Novera Alam, Md Amin Hossain, Gerd Mikus & David J. Greenblatt. (2018) In vitro inhibition of human UGT isoforms by ritonavir and cobicistat. Xenobiotica 48:8, pages 764-769.
Read now
Read now
Aleksi Tornio, Pertti J. Neuvonen, Mikko Niemi & Janne T. Backman. (2017) Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters. Expert Opinion on Drug Metabolism & Toxicology 13:1, pages 83-95.
Read now
Read now
Agnieszka Potęga, Barbara Fedejko-Kap & Zofia Mazerska. (2016) Mechanism-based inactivation of human cytochrome P450 1A2 and 3A4 isoenzymes by anti-tumor triazoloacridinone C-1305. Xenobiotica 46:12, pages 1056-1065.
Read now
Read now
Robert J Riley & Claire E Wilson. (2015) Cytochrome P450 time-dependent inhibition and induction: advances in assays, risk analysis and modelling. Expert Opinion on Drug Metabolism & Toxicology 11:4, pages 557-572.
Read now
Read now
Pietro Palatini, Rocco Orlando & Sara De Martin. (2010) The effect of liver disease on inhibitory and plasma protein-binding displacement interactions: an update. Expert Opinion on Drug Metabolism & Toxicology 6:10, pages 1215-1230.
Read now
Read now
Howard J. Burt, Aleksandra Galetin & J. Brian Houston. (2010) IC50-based approaches as an alternative method for assessment of time-dependent inhibition of CYP3A4. Xenobiotica 40:5, pages 331-343.
Read now
Read now
Zhi-Wei Zhou & Shu-Feng Zhou. (2009) Application of mechanism-based CYP inhibition for predicting drug–drug interactions. Expert Opinion on Drug Metabolism & Toxicology 5:6, pages 579-605.
Read now
Read now
S. Choi, B. Sainz$suffix/text()$suffix/text(), P. Corcoran, S. Uprichard & H. Jeong. (2009) Characterization of increased drug metabolism activity in dimethyl sulfoxide (DMSO)-treated Huh7 hepatoma cells. Xenobiotica 39:3, pages 205-217.
Read now
Read now
Articles from other publishers (54)
Jing Gao, Yuanjin Zhang, Xueqin Lei, Yuan Xu, Zhenliang Sun & Xin Wang. (2022) Risk assessment of the inhibition of hydroxygenkwanin on human and rat cytochrome P450 by cocktail method. Toxicology in Vitro 79, pages 105281.
Crossref
Crossref
Zhongbo Shi, Junhao Jiang, Dezhang Zhao, Baogang Xie, Yan Li & Chao Yu. (2022) Effects of Astragaloside IV on the Pharmacokinetics of Metoprolol in Rats and its
Mechanism. Current Drug Metabolism 23:2, pages 131-136.
Crossref
Crossref
Siva Nageswara Rao Gajula, Megha Sajakumar Pillai, Gananadhamu Samanthula & Rajesh Sonti. (2021) Cytochrome P450 enzymes: a review on drug metabolizing enzyme inhibition studies in drug discovery and development. Bioanalysis 13:17, pages 1355-1378.
Crossref
Crossref
Jaydeep Yadav, Erickson Paragas, Ken Korzekwa & Swati Nagar. (2020) Time-dependent enzyme inactivation: Numerical analyses of in vitro data and prediction of drug-drug interactions. Pharmacology & Therapeutics 206, pages 107449.
Crossref
Crossref
Diane Ramsden, Conrad Fung, Niresh Hariparsad, Jane R. Kenny, Michael Mohutsky, Neil J. Parrott, Sarah Robertson & Donald J. Tweedie. (2019) Perspectives from the Innovation and Quality Consortium Induction Working Group on Factors Impacting Clinical Drug-Drug Interactions Resulting from Induction: Focus on Cytochrome 3A Substrates. Drug Metabolism and Disposition 47:10, pages 1206-1221.
Crossref
Crossref
Yi Cheng, Shuowen Tang, Ang Chen, Yuanjin Zhang, Mingyao Liu & Xin Wang. (2019) Evaluation of the inhibition risk of shikonin on human and rat UDP-glucuronosyltransferases (UGT) through the cocktail approach. Toxicology Letters 312, pages 214-221.
Crossref
Crossref
Dhruba Dhar, Shounak Roy & Vinod Kumar Nigam. 2019. Tools, Techniques and Protocols for Monitoring Environmental Contaminants. Tools, Techniques and Protocols for Monitoring Environmental Contaminants
207
229
.
Robert Hermann, Hartmut Derendorf, Oliver von Richter & Amin Rostami-Hodjegan. (2018) Core Entrustable Professional Activities in Clinical Pharmacology: Pearls for Clinical Practice. The Journal of Clinical Pharmacology 58:6, pages 704-716.
Crossref
Crossref
Sijie Lu, R. A. Nand, J. S. Yang, Gang Chen & A. S. Gross. (2017) Pharmacokinetics of CYP2C9, CYP2C19, and CYP2D6 substrates in healthy Chinese and European subjects. European Journal of Clinical Pharmacology 74:3, pages 285-296.
Crossref
Crossref
Elisa A. M. Calvier, Elke H. J. Krekels, Huixin Yu, Pyry A. J. Välitalo, Trevor N. Johnson, Amin Rostami‐Hodjegan, Dick Tibboel, Piet H. van der Graaf, Meindert Danhof & Catherijne A. J. Knibbe. (2018) Drugs Being Eliminated via the Same Pathway Will Not Always Require Similar Pediatric Dose Adjustments. CPT: Pharmacometrics & Systems Pharmacology 7:3, pages 175-185.
Crossref
Crossref
Chien‐Wei Chiang, Pengyue Zhang, Xueying Wang, Lei Wang, Shijun Zhang, Xia Ning, Li Shen, Sara K. Quinney & Lang Li. (2017) Translational High‐Dimensional Drug Interaction Discovery and Validation Using Health Record Databases and Pharmacokinetics Models. Clinical Pharmacology & Therapeutics 103:2, pages 287-295.
Crossref
Crossref
Loubna El Harrad, Ilhame Bourais, Hasna Mohammadi & Aziz Amine. (2018) Recent Advances in Electrochemical Biosensors Based on Enzyme Inhibition for Clinical and Pharmaceutical Applications. Sensors 18:2, pages 164.
Crossref
Crossref
Sanaz Jamshidfar, Yalda H. Ardakani, Hoda Lavasani & Mohammadreza Rouini. (2017) Inhibition of mirtazapine metabolism by Ecstasy (MDMA) in isolated perfused rat liver model. DARU Journal of Pharmaceutical Sciences 25:1.
Crossref
Crossref
Daniel Moj, Nina Hanke, Hannah Britz, Sebastian Frechen, Tobias Kanacher, Thomas Wendl, Walter Emil Haefeli & Thorsten Lehr. (2016) Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug–Drug Interactions and Co-medication Regimens. The AAPS Journal 19:1, pages 298-312.
Crossref
Crossref
Bianca M. Liederer, Xingrong Liu, Simon Wong & Daniel R. Mudra. 2017. Translating Molecules into Medicines. Translating Molecules into Medicines
165
230
.
Manisha Bhateria, Rachumallu Ramakrishna, Santosh Kumar Puttrevu, Anil K. Saxena & Rabi Sankar Bhatta. (2016) Enantioselective inhibition of Cytochrome P450-mediated drug metabolism by a novel antithrombotic agent, S002-333: Major effect on CYP2B6. Chemico-Biological Interactions 256, pages 257-265.
Crossref
Crossref
Ang Chen, Xiaojing Zhou, Shuowen Tang, Mingyao Liu & Xin Wang. (2016) Evaluation of the inhibition potential of plumbagin against cytochrome P450 using LC-MS/MS and cocktail approach. Scientific Reports 6:1.
Crossref
Crossref
R. S. Sane, D. Ramsden, J. P. Sabo, C. Cooper, L. Rowland, N. Ting, A. Whitcher-Johnstone & D. J. Tweedie. (2015) Contribution of Major Metabolites toward Complex Drug-Drug Interactions of Deleobuvir: In Vitro Predictions and In Vivo Outcomes. Drug Metabolism and Disposition 44:3, pages 466-475.
Crossref
Crossref
Pietro Palatini. (2016) Pharmacokinetic drug interactions in liver disease: An update. World Journal of Gastroenterology 22:3, pages 1260.
Crossref
Crossref
Yong Zhao, Bent Håvard Hellum, Aihua Liang & Odd Georg Nilsen. (2015) Inhibitory Mechanisms of Human CYPs by Three Alkaloids Isolated from Traditional Chinese Herbs. Phytotherapy Research 29:6, pages 825-834.
Crossref
Crossref
Ken Korzekwa, Donald Tweedie, Upendra A. Argikar, Andrea Whitcher-Johnstone, Leslie Bell, Shari Bickford & Swati Nagar. (2014) A Numerical Method for Analysis of In Vitro Time-Dependent Inhibition Data. Part 2. Application to Experimental Data. Drug Metabolism and Disposition 42:9, pages 1587-1595.
Crossref
Crossref
Swati Nagar, Jeffrey P. Jones & Ken Korzekwa. (2014) A Numerical Method for Analysis of In Vitro Time-Dependent Inhibition Data. Part 1. Theoretical Considerations. Drug Metabolism and Disposition 42:9, pages 1575-1586.
Crossref
Crossref
Vamshi K. Manda, Olivia R. Dale, Charles Awortwe, Zulfiqar Ali, Ikhlas A. Khan, Larry A. Walker & Shabana I. Khan. (2014) Evaluation of drug interaction potential of Labisia pumila (Kacip Fatimah) and its constituents. Frontiers in Pharmacology 5.
Crossref
Crossref
Sarah K. Lawrence, Dung Nguyen, Chet Bowen, Lauren Richards-Peterson & Konstantine W. Skordos. (2014) The Metabolic Drug-Drug Interaction Profile of Dabrafenib: In Vitro Investigations and Quantitative Extrapolation of the P450-Mediated DDI Risk. Drug Metabolism and Disposition 42:7, pages 1180-1190.
Crossref
Crossref
Scott J. Brantley, Aneesh A. Argikar, Yvonne S. Lin, Swati Nagar & Mary F. Paine. (2014) Herb–Drug Interactions: Challenges and Opportunities for Improved Predictions. Drug Metabolism and Disposition 42:3, pages 301-317.
Crossref
Crossref
Brian W. Ogilvie & Andrew Parkinson. 2014. Handbook of Metabolic Pathways of Xenobiotics. Handbook of Metabolic Pathways of Xenobiotics
1
21
.
Gary W. Caldwell & Zhengyin Yan. 2014. Optimization in Drug Discovery. Optimization in Drug Discovery
315
336
.
Andrew V. Stachulski, Thomas A. Baillie, B. Kevin Park, R. Scott Obach, Deepak K. Dalvie, Dominic P. Williams, Abhishek Srivastava, Sophie L. Regan, Daniel J. Antoine, Christopher E. P. Goldring, Alvin J. L. Chia, Neil R. Kitteringham, Laura E. Randle, Hayley Callan, J. Luis Castrejon, John Farrell, Dean J. Naisbitt & Martin S. Lennard. (2013) The Generation, Detection, and Effects of Reactive Drug Metabolites. Medicinal Research Reviews 33:5, pages 985-1080.
Crossref
Crossref
Alexander V. LyubimovKarthik Venkatakrishnan. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
62
.
Ji-Yoon Lee, Sang Yoon Lee, Soo Jin Oh, Ki Ho Lee, Young Suk Jung & Sang Kyum Kim. (2012) Assessment of drug–drug interactions caused by metabolism-dependent cytochrome P450 inhibition. Chemico-Biological Interactions 198:1-3, pages 49-56.
Crossref
Crossref
. 2012. Pharmacokinetics and Metabolism in Drug Design. Pharmacokinetics and Metabolism in Drug Design
159
208
.
Evan J. Friedman, Iain P. Fraser, Ying-Hong Wang, Arthur J. Bergman, Chi-Chung Li, Patrick J. Larson, Jeffrey Chodakewitz, John A. Wagner & S. Aubrey Stoch. (2011) Effect of Different Durations and Formulations of Diltiazem on the Single-Dose Pharmacokinetics of Midazolam: How Long Do We Go?. The Journal of Clinical Pharmacology 51:11, pages 1561-1570.
Crossref
Crossref
Carole E. Shardlow, Grant T. Generaux, Christopher C. MacLauchlin, Nicoletta Pons, Konstantine W. Skordos & Jackie C. Bloomer. (2011) Utilizing Drug-Drug Interaction Prediction Tools during Drug Development: Enhanced Decision Making Based on Clinical Risk. Drug Metabolism and Disposition 39:11, pages 2076-2084.
Crossref
Crossref
J Honkalammi, M Niemi, P J Neuvonen & J T Backman. (2011) Mechanism-Based Inactivation of CYP2C8 by Gemfibrozil Occurs Rapidly in Humans. Clinical Pharmacology & Therapeutics 89:4, pages 579-586.
Crossref
Crossref
Yusuke Masuo, Kousei Ito, Takehito Yamamoto, Akihiro Hisaka, Masashi Honma & Hiroshi Suzuki. (2010) Characterization of Inhibitory Effect of Carbapenem Antibiotics on the Deconjugation of Valproic Acid Glucuronide. Drug Metabolism and Disposition 38:10, pages 1828-1835.
Crossref
Crossref
Doaa Elsherbiny, Yuan Ren, Helen McIlleron, Gary Maartens & Ulrika S. H. Simonsson. (2010) Population pharmacokinetics of lopinavir in combination with rifampicin-based antitubercular treatment in HIV-infected South African children. European Journal of Clinical Pharmacology 66:10, pages 1017-1023.
Crossref
Crossref
Kiyomi Ito & Yuichi Sugiyama. (2010) Use of clearance concepts and modeling techniques in the prediction of metabolic drug–drug interactions. Trends in Pharmacological Sciences 31:8, pages 351-355.
Crossref
Crossref
Thomas M. Polasek, Janani S. Sadagopal, David J. Elliot & John O. Miners. (2009) In vitro-in vivo extrapolation of zolpidem as a perpetrator of metabolic interactions involving CYP3A. European Journal of Clinical Pharmacology 66:3, pages 275-283.
Crossref
Crossref
Akihiro Hisaka, Yoshiyuki Ohno, Takehito Yamamoto & Hiroshi Suzuki. (2010) Prediction of pharmacokinetic drug–drug interaction caused by changes in cytochrome P450 activity using in vivo information. Pharmacology & Therapeutics 125:2, pages 230-248.
Crossref
Crossref
Byeong-Woo ParkHyung Seok Park. (2010) Adjuvant Hormonal Therapy: Current Standard and Practical Issues. Journal of Breast Cancer 13:3, pages 242.
Crossref
Crossref
Akihiro Hisaka, Yoshiyuki Ohno, Takehito Yamamoto & Hiroshi Suzuki. (2010) Theoretical Considerations on Quantitative Prediction of Drug-Drug Interactions. Drug Metabolism and Pharmacokinetics 25:1, pages 48-61.
Crossref
Crossref
Ragini Vuppugalla, Sean Kim, Tatyana Zvyaga, Yong-hae Han, Praveen Balimane, Punit Marathe & A. David Rodrigues. 2010. Enzyme- and Transporter-Based Drug-Drug Interactions. Enzyme- and Transporter-Based Drug-Drug Interactions
585
624
.
R. Scott Obach, Odette A. Fahmi & Robert L. Walsky. 2010. Enzyme- and Transporter-Based Drug-Drug Interactions. Enzyme- and Transporter-Based Drug-Drug Interactions
473
495
.
Frederique Fenneteau, Patrick Poulin & Fahima Nekka. (2010) Physiologically Based Predictions of the Impact of Inhibition of Intestinal and Hepatic Metabolism on Human Pharmacokinetics of CYP3A Substrates. Journal of Pharmaceutical Sciences 99:1, pages 486-514.
Crossref
Crossref
Janne T. Backman, Johanna Honkalammi, Mikko Neuvonen, Kaisa J. Kurkinen, Aleksi Tornio, Mikko Niemi & Pertti J. Neuvonen. (2009) CYP2C8 Activity Recovers within 96 Hours after Gemfibrozil Dosing: Estimation of CYP2C8 Half-Life Using Repaglinide as an in Vivo Probe. Drug Metabolism and Disposition 37:12, pages 2359-2366.
Crossref
Crossref
Amit S. Kalgutkar & Mary T. Didiuk. (2009) Structural Alerts, Reactive Metabolites, and Protein Covalent Binding: How Reliable Are These Attributes as Predictors of Drug Toxicity?. Chemistry & Biodiversity 6:11, pages 2115-2137.
Crossref
Crossref
Akihiro Hisaka, Makiko Kusama, Yoshiyuki Ohno, Yuichi Sugiyama & Hiroshi Suzuki. (2009) A Proposal for a Pharmacokinetic Interaction Significance Classification System (PISCS) Based on Predicted Drug Exposure Changes and Its Potential Application to Alert Classifications in Product Labelling. Clinical Pharmacokinetics 48:10, pages 653-666.
Crossref
Crossref
Ruth Hyland, R. Scott Obach, Chad Stoner, Michael West, Michael R. Wester, Kuresh Youdim & Michael Zientek. 2009. Hit and Lead Profiling. Hit and Lead Profiling
165
196
.
Scott W. Grimm, Heidi J. Einolf, Steven D. Hall, Kan He, Heng-Keang Lim, Kah-Hiing John Ling, Chuang Lu, Amin A. Nomeir, Eleanore Seibert, Konstantine W. Skordos, George R. Tonn, Robert Van Horn, Regina W. Wang, Y. Nancy Wong, Tian J. Yang & R. Scott Obach. (2009) The Conduct of in Vitro Studies to Address Time-Dependent Inhibition of Drug-Metabolizing Enzymes: A Perspective of the Pharmaceutical Research and Manufacturers of America. Drug Metabolism and Disposition 37:7, pages 1355-1370.
Crossref
Crossref
Kenneth H. Grime, James Bird, Douglas Ferguson & Robert J. Riley. (2009) Mechanism-based inhibition of cytochrome P450 enzymes: An evaluation of early decision making in vitro approaches and drug–drug interaction prediction methods. European Journal of Pharmaceutical Sciences 36:2-3, pages 175-191.
Crossref
Crossref
Dominic O. Hull, Besnik Bajrami, Ingela Jansson, John B. Schenkman & James F. Rusling. (2008) Characterizing Metabolic Inhibition Using Electrochemical Enzyme/DNA Biosensors. Analytical Chemistry 81:2, pages 716-724.
Crossref
Crossref
J. Matthew Hutzler, Larissa M. Balogh, Michael Zientek, Vikas Kumar & Timothy S. Tracy. (2009) Mechanism-Based Inactivation of Cytochrome P450 2C9 by Tienilic Acid and (±)-Suprofen: A Comparison of Kinetics and Probe Substrate Selection. Drug Metabolism and Disposition 37:1, pages 59-65.
Crossref
Crossref
Barry C. Jones, Donald S. Middleton & Kuresh Youdim. 2009. Progress in Medicinal Chemistry Volume 47. Progress in Medicinal Chemistry Volume 47
239
263
.
Peter H. Bui, Arnulfo Quesada, Adrian Handforth & Oliver Hankinson. (2008) The Mibefradil Derivative NNC55-0396, a Specific T-Type Calcium Channel Antagonist, Exhibits Less CYP3A4 Inhibition than Mibefradil. Drug Metabolism and Disposition 36:7, pages 1291-1299.
Crossref
Crossref